ScholarIQanswers from OpenAlex & ORCID
Mark S. Freedman
ResearcherPublications, citations & collaboration network
Mark S. Freedman is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Mark S. Freedman have?
ScholarIQindexed works
Mark S. Freedman has 423 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Mark S. Freedman have?
ScholarIQcitation count
Mark S. Freedman has 16,427 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Mark S. Freedman?
ScholarIQh-index
Mark S. Freedman has an h-index of 64 in OpenAlex.
What is the i10-index of Mark S. Freedman?
ScholarIQi10-index
Mark S. Freedman has an i10-index of 200 in OpenAlex.
What is the ORCID of Mark S. Freedman?
ScholarIQorcid
The ORCID for Mark S. Freedman is on the source record.
What is the OpenAlex record for Mark S. Freedman?
ScholarIQopenalex
The OpenAlex for Mark S. Freedman is on the source record.
What are the most-cited papers on Mark S. Freedman?
ScholarIQmost cited works
Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement.
Mark S. Freedman, Edward J. Thompson, Florian Deisenhammer, Gavin Giovannoni, G. Grimsley, Geoffrey Keir, Sten Öhman, Michael K. Racke, Mohammad K. Sharief, Christian Sindic, Finn Sellebjerg, Wallace W. Tourtellotte
Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
Paolo A. Muraro, Marcelo C. Pasquini, Harold Atkins, James D. Bowen, Dominique Farge, Αthanasios Fassas, Mark S. Freedman, George E. Georges, Francesca Gualandi, Nelson Hamerschlak, Eva Havrdová, Vasilios Κ. Kimiskidis, Tomáš Kozák, Giovanni L. Mancardi, Luca Massacesi, Daniela A. Moraes, Richard A. Nash, Steven Z. Pavletic, Jian Ouyang, Montserrat Rovira, Albert Saiz, Belinda Pinto Simões, Marek Trněný, Lin Zhu, Manuela Badoglio, Xiaobo Zhong, Maria Pia Sormani, Riccardo Saccardi, for the Multiple Sclerosis–Autologous Hematopoietic Stem Cell Transplantation (MS-AHSCT) Long-term Outcomes Study Group